Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Reaffirms Neutral Rating for Orthofix Medical with Increased Price Target

Elaine Mendonca by Elaine Mendonca
March 7, 2024
in Breaking News
0
Healthcare cloud based
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

On March 7, 2024, analyst Jason Wittes from Roth MKM reaffirmed a Neutral rating for Orthofix Medical (NASDAQ:OFIX) and increased the price target to $15. The average price target for Orthofix is $18.00 according to short-term forecasts from three analysts, with estimates ranging from $12.00 to $28.00.

Orthofix Medical Inc. (OFIX) Sees Modest Increase in Stock Price on March 7, 2024

On March 7, 2024, Orthofix Medical Inc. (OFIX) saw a modest increase in its stock price. According to data from CNN Money, OFIX shares increased by $0.01 since the market last closed, representing a 0.07% rise. The stock opened at $14.24 on March 7, which was $0.11 higher than its previous close. This slight uptick in price momentum may indicate some positive sentiment among investors towards Orthofix Medical Inc. However, it is important to note that the stock is still trading below its 200-day simple moving average. Despite the small increase in price on March 7, OFIX is still trading in the middle of its 52-week range. Investors may want to keep an eye on any upcoming developments or news related to Orthofix Medical Inc. Overall, while OFIX saw a slight uptick in its stock price on March 7, it is important for investors to consider the broader market context and any potential catalysts that could influence the stock’s performance in the coming days and weeks.

OFIX Stock Sees Mixed Performances in Financials on March 7, 2024: Revenue Up, Net Income Down

On March 7, 2024, OFIX stock saw mixed performances in terms of its financials. According to data from CNN Money, the company reported a total revenue of $746.64 million for the past year, with a significant increase of 62.06% compared to the previous year. However, the total revenue remained flat at $200.41 million for the last quarter.

In terms of net income, OFIX reported a loss of $151.40 million for the past year, representing a decrease of 666.6% compared to the previous year. On a positive note, the net income improved by 23.16% to -$22.17 million for the last quarter.

Earnings per share (EPS) also saw a decline for OFIX stock. The company reported an EPS of -$4.12 for the past year, which is a decrease of 318.55% compared to the previous year. However, the EPS remained unchanged at -$0.59 for the last quarter.

Overall, the mixed performances in the financials of OFIX stock on March 7, 2024, indicate that the company is facing challenges in terms of profitability. Investors may want to closely monitor the company’s financials and performance in the upcoming quarters to assess its long-term growth potential.

Tags: OFIX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
The Rise of Strategic Partnerships in Life Sciences: Trends Shaping the Future of Healthcare Innovation

Intels Strategic Expansion Securing Government Grants for Military Chip Production and AI Development

SherwinWilliams Receives Upgrade from UBS Poised for Growth in US Housing Market

Healthcare cloud based

FDA Approval of CELZ201 Marks Milestone in Fight Against Type 1 Diabetes Mellitus

Recommended

Fiserv Stock

Fiserv Shares Struggle to Gain Traction Amid Investor Doubts

3 weeks ago
Cooper-Standard Stock

Cooper-Standard Shares Plunge on Disappointing Earnings Report

3 months ago
Volatus Aerospace Stock

Volatus Aerospace Expands Defense and Environmental Technology Operations

5 months ago
FCBC stock news

Symmetry Partners LLC Acquires Significant Position in Carnival Co. & plc, Expresses Optimism for Future Growth

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Diginex Enters Critical Implementation Phase Following Strategic Moves

Deluxe Stock Gains Momentum on Successful Fintech Transition

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

Tellurian Acquisition Finalized as Woodside Takes Control

Trending

Embecta Stock
Earnings

Embecta’s Q1 Performance Outpaces Analyst Forecasts

by Rodolfo Hanigan
February 7, 2026
0

Medical device company Embecta reported financial results for the first quarter of fiscal year 2026 on Thursday,...

Camping World Stock

Camping World’s New Leadership Faces First Major Test

February 7, 2026
Viking Therapeutics Stock

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

February 7, 2026
Diginex Stock

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026
Deluxe Stock

Deluxe Stock Gains Momentum on Successful Fintech Transition

February 6, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Embecta’s Q1 Performance Outpaces Analyst Forecasts
  • Camping World’s New Leadership Faces First Major Test
  • Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com